TG THERAPEUTICS, INC. Revenue Recognition, Sales Returns, Reserve for Sales Returns
TG THERAPEUTICS, INC. (TGTX) reported Revenue Recognition, Sales Returns, Reserve for Sales Returns of $600.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Notes
us-gaap:RevenueRecognitionSalesReturnsReserveForSalesReturns · last filed 2023-03-01
- TG THERAPEUTICS, INC. revenue recognition, sales returns, reserve for sales returns for fiscal 2022 was $600.00K.
| Period end | Revenue Recognition, Sales Returns, Reserve for Sales Returns 12 month |
|---|---|
| 2022-12-31 | $600.00K 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |